MoonLake Immunotherapeutics
NASDAQ:MLTXBiotechnology
+$0.13 today
- Market cap
- $957.45M
- Beta
- 1.04
- P/E (TTM)
- -5.4
- EPS (TTM)
- -$3.61
Volume 1.17M
Average 0.99M
Returns on capital
MoonLake Immunotherapeutics management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-74.7%
avg 41.6%
ROIC
-64.4%
avg -281.7%
ROA
-53.6%
avg -117.4%
Analysis
ROA is currently the strongest return metric at -53.6% versus its period average of -117.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Kristian Reich | Co-Founder & Chief Scientific Officer | USD 795.47K | 60 | 2.71M | 3.68% |
Jorge Santos da Silva | Co-Founder, Interim Chair of the Board & CEO | USD 787.31K | 49 | 2.77M | 3.77% |
Matthias Bodenstedt | Chief Financial Officer | USD 626.53K | 38 | 1.12M | 1.52% |
Luciana Marques | Associate Vice-President of HR, People and Culture | — | — | — | — |
Nicolas Mosimann | General Counsel | — | — | — | — |
Tino Anthamatten | Vice President of Marketing, Market Access & Pricing | — | — | — | — |
Oliver Daltrop | Chief Technical Officer | — | — | — | — |
Carla Bretes | Director of Investor Relations & External Communications | — | — | — | — |
Nuala Brennan | Chief Clinical Development Officer | — | — | — | — |
Joana Cortez | Associate Vice-President of Legal & Compliance | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 27, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
27
$83.03M
Net Transaction Value
−$83.03M
Net selling
Most Active
Reich Kristian
10 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jul 27, 26Jul 27, 2026 | Reich Kristian Indirect | Sell | $22K$22,000.00 |
| Jul 22, 26Jul 22, 2026 | Reich Kristian Indirect | Sell | $49K$48,960.00 |
| Jul 21, 26Jul 21, 2026 | Reich Kristian Indirect | Sell | $1M$1,001,000.00 |
| Jul 20, 26Jul 20, 2026 | Reich Kristian Indirect | Sell | $877.9K$877,933.00 |
| Jul 15, 26Jul 15, 2026 | Reich Kristian Indirect | Sell | $322.3K$322,261.05 |
| Jul 10, 26Jul 10, 2026 | Santos da Silva Jorge Direct | Sell | $1.4M$1,367,145.78 |
| Jul 9, 26Jul 9, 2026 | Santos da Silva Jorge Direct | Sell | $679.1K$679,059.36 |
| Jul 1, 26Jul 1, 2026 | Santos da Silva Jorge Direct | Sell | $956.9K$956,933.25 |
| Jun 22, 26Jun 22, 2026 | Bodenstedt Matthias Direct | Sell | $862.2K$862,204.80 |
| Jun 18, 26Jun 18, 2026 | Bodenstedt Matthias Direct | Sell | $54.8K$54,762.40 |
1–10 of 27
Summary
Insiders reported 0 buys worth $0.00 and 27 sells worth $83.03M over the last 12 months. That adds up to net selling of $83.03M. Reich Kristian was the most active insider with 10 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does MoonLake Immunotherapeutics compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about MLTX's management, answered from reported figures.
Who manages MLTX?
MoonLake Immunotherapeutics (MLTX) lists 10 active executives. The top listed executive is Luciana Marques, Associate Vice-President of HR, People and Culture.
Are MLTX insiders buying or selling?
Recent insider activity shows net selling of $144.39M.
Continue the stock analysis
Jump to another research area for this company.